Read by QxMD icon Read


Paul Calès, Jérôme Boursier, Frédéric Oberti, Valérie Moal, Isabelle Fouchard Hubert, Sandrine Bertrais, Gilles Hunault, Marie Christine Rousselet
Fibrosis blood tests are usually developed using significant fibrosis, which is a unique diagnostic target; however, these tests are employed for other diagnostic targets, such as cirrhosis. We aimed to improve fibrosis staging accuracy by simultaneously targeting biomarkers for several diagnostic targets. A total of 3,809 patients were included, comprising 1,012 individuals with chronic hepatitis C (CHC) into a derivation population and 2,797 individuals into validation populations of different etiologies (CHC, chronic hepatitis B, human immunodeficiency virus/CHC, nonalcoholic fatty liver disease, alcohol) using Metavir fibrosis stages as reference...
April 2018: Hepatology Communications
Philippe Foubert, Diana Zafra, Mike Liu, Rohit Rajoria, Damian Gutierrez, Mayer Tenenhaus, John K Fraser
BACKGROUND: Effective prevention and treatment of hypertrophic scars (HTSs), a common consequence of deep-partial thickness injury, remain a significant clinical challenge. Previous studies from our group have shown that autologous adipose-derived regenerative cells (ADRCs) represent a promising approach to improve wound healing and, thereby, impact HTS development. The purpose of this study was to assess the influence of local delivery of ADRCs immediately following deep-partial thickness cutaneous injury on HTS development in the red Duroc (RD) porcine model...
November 15, 2017: Stem Cell Research & Therapy
Eugenia Tsai, Tai-Ping Lee
The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) are increasing and identification of people at risk of disease progression is extremely important. The current gold standard for diagnosing NAFLD/nonalcoholic steatohepatitis (NASH) is by liver biopsy, but it has several limitations. Noninvasive tests via biomarkers and transient elastography to assess NAFLD/NASH are being used in clinical practice. The most validated diagnostic panels include the NAFLD fibrosis score, FIB-4 (Fibrosis-4), and FibroMeter...
February 2018: Clinics in Liver Disease
Alexandra Ducancelle, Vincent Leroy, Julien Vergniol, Nathalie Sturm, Brigitte Le Bail, Jean Pierre Zarski, Eric Nguyen Khac, Dominique Salmon, Victor de Ledinghen, Paul Calès
BACKGROUND AND GOAL: International guidelines suggest combining a blood test and liver stiffness measurement (LSM) to stage liver fibrosis in chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). Therefore, we compared the accuracies of these tests between the main etiologies of chronic liver diseases. STUDY: Overall, 1968 patients were included in 5 etiologies: CHC: 698, chronic hepatitis B: 152, human immunodeficiency virus/CHC: 628, NAFLD: 225, and alcoholic liver disease (ALD): 265...
August 2017: Journal of Clinical Gastroenterology
Ludmia Taibi, Anders Boyd, Nelly Bosselut, Julie Bottero, Jérôme Guéchot, Karine Lacombe, Elisabeth Lasnier, Bruno Baudin, Michel Vaubourdolle
Background Non-invasive methods for assessing liver fibrosis are increasingly used as an alternative to liver biopsy. Recently, a score-based biochemical blood test (Coopscore© ) was developed in a cohort of patients chronically infected with hepatitis C virus, showing higher diagnostic performances than Fibrometer®, Fibrotest®, Hepascore® and Fibroscan™. Here, we assess its performance in patients co-infected with the human immunodeficiency virus and hepatitis B virus. Methods Ninety-seven human immunodeficiency virus/hepatitis B virus co-infected patients with liver biopsies were included from a previously described cohort...
March 2018: Annals of Clinical Biochemistry
Maria Chiara Chindamo, Jerome Boursier, Ronir Raggio Luiz, Isabelle Fouchard-Hubert, Vera Lúcia Nunes Pannain, João Marcello de Araújo Neto, Henrique Sérgio Moraes Coelho, Renata de Mello Perez, Paul Calès, Cristiane Alves Villela-Nogueira
AIM: To evaluate the performance of FibroMeter(Virus3G) combined to the first generation tests aspartate aminotransferase-to-platelet ratio index (APRI) or Forns index to assess significant fibrosis in chronic hepatitis C (CHC). METHODS: First generation tests APRI or Forns were initially applied in a derivation population from Rio de Janeiro in Brazil considering cut-offs previously reported in the literature to evaluate significant fibrosis. FibroMeter(Virus3G) was sequentially applied to unclassified cases from APRI or Forns...
February 28, 2017: World Journal of Hepatology
P Calès, J Boursier, J Lebigot, V de Ledinghen, C Aubé, I Hubert, F Oberti
BACKGROUND: In chronic hepatitis C, the European Association for the Study of the Liver and the Asociacion Latinoamericana para el Estudio del Higado recommend performing transient elastography plus a blood test to diagnose significant fibrosis; test concordance confirms the diagnosis. AIM: To validate this rule and improve it by combining a blood test, FibroMeter (virus second generation, Echosens, Paris, France) and transient elastography (constitutive tests) into a single combined test, as suggested by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America...
April 2017: Alimentary Pharmacology & Therapeutics
Jérôme Boursier, Victor de Ledinghen, Vincent Leroy, Rodolphe Anty, Sven Francque, Dominique Salmon, Adrien Lannes, Sandrine Bertrais, Frederic Oberti, Isabelle Fouchard-Hubert, Paul Calès
BACKGROUND & AIMS: Chronic liver diseases (CLD) are common, and are therefore mainly managed by non-hepatologists. These physicians lack access to the best non-invasive tests of liver fibrosis, and consequently cannot accurately determine the disease severity. Referral to a hepatologist is then needed. We aimed to implement an algorithm, comprising a new first-line test usable by all physicians, for the detection of advanced liver fibrosis in all CLD patients. METHODS: Diagnostic study: 3754 CLD patients with liver biopsy were 2:1 randomized into derivation and validation sets...
June 2017: Journal of Hepatology
Thomson Chi-Wang Loong, Jeremy Lok Wei, Jonathan Chung-Fai Leung, Grace Lai-Hung Wong, Sally She-Ting Shu, Angel Mei-Ling Chim, Anthony Wing-Hung Chan, Paul Cheung-Lung Choi, Yee-Kit Tse, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
BACKGROUND AND AIM: The FibroMeter vibration-controlled transient elastography (FM VCTE) is a new formula combining the serum test FM and liver stiffness measurement (LSM) by VCTE. We tested the accuracy and utility of FM VCTE for fibrosis staging in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: Two hundred fifteen NAFLD patients with LSM, FM NAFLD, FM VCTE, and other serum tests (aspartate aminotransferase-to-platelet ratio index, fibrosis-4 index, BARD score, NAFLD fibrosis score, and aspartate aminotransferase-to-alanine aminotransferase ratio) performed 1 day before liver biopsy were evaluated...
July 2017: Journal of Gastroenterology and Hepatology
Sandrine Bertrais, Jérôme Boursier, Alexandra Ducancelle, Frédéric Oberti, Isabelle Fouchard-Hubert, Valérie Moal, Paul Calès
BACKGROUND AND AIM: There is currently no recommended time interval between noninvasive fibrosis measurements for monitoring chronic liver diseases. We determined how long a single liver fibrosis evaluation may accurately predict mortality, and assessed whether combining tests improves prognostic performance. METHODS: We included 1559 patients with chronic liver disease and available baseline liver stiffness measurement (LSM) by Fibroscan, aspartate aminotransferase to platelet ratio index (APRI), FIB-4, Hepascore, and FibroMeterV2G ...
June 2017: Journal of Gastroenterology and Hepatology
Sudeep Tanwar, Paul M Trembling, Brian J Hogan, Julie Parkes, Scott Harris, Paul Grant, Eleni Nastouli, Mathias Ocker, Klaus Wehr, Christoph Herold, Daniel Neureiter, Detlef Schuppan, William M Rosenberg
BACKGROUND: Advancing fibrosis is regarded as the most important factor when stratifying patients with chronic hepatitis C for retreatment. GOALS: (1) To compare the performance of 10 biomarkers of fibrosis, including patented tests, among patients with chronic hepatitis C and treatment failure; and (2) to assess the impact on biomarker performance of using 2 different assays of hyaluronic acid (HA). STUDY: For 80 patients, liver histology (Metavir) was compared with biomarker scores using sera obtained within 6 months of liver biopsy (indirect biomarkers: AST:ALT ratio, APRI, Forns index, FIB-4, Fibrometer V3G; direct biomarkers: ELF, Fibrospect II, Hyaluronic acid-HA, Fibrometer V2G, Hepascore)...
March 2017: Journal of Clinical Gastroenterology
Marco Merli, Laura Galli, Antonella Castagna, Stefania Salpietro, Nicola Gianotti, Emanuela Messina, Andrea Poli, Giulia Morsica, Sabrina Bagaglio, Massimo Cernuschi, Alba Bigoloni, Caterina Uberti-Foppa, Adriano Lazzarin, Hamid Hasson
We determined the diagnostic accuracy and optimal cut off of three indirect fibrosis biomarkers (APRI, FIB-4, Forns) compared with liver stiffness (LS) for the detection of liver cirrhosis in HIV/HCV-coinfected patients. An observational retrospective study on HIV/HCV-coinfected patients with concomitant LS measurement and APRI, FIB-4 and Forns was performed. The presence of liver cirrhosis was defined as a LS ≥13 KPa. The diagnostic accuracy and optimal cut-off values, compared with LS categorization (<13 vs ≥13 KPa), were determined by receiver operating characteristics (ROC) curves...
2016: New Microbiologica
Wojciech Trzepizur, Jérôme Boursier, Yasmina Mansour, Marc Le Vaillant, Sylvaine Chollet, Thierry Pigeanne, Acya Bizieux-Thaminy, Marie-Pierre Humeau, Claire Alizon, François Goupil, Nicole Meslier, Pascaline Priou, Paul Calès, Frédéric Gagnadoux
Obstructive sleep apnea (OSA) may contribute to the development of nonalcoholic fatty liver disease. We performed a multisite cross-sectional study to evaluate the association between the severity of OSA and blood markers of liver steatosis (using the hepatic steatosis index), cytolysis (based on alanine aminotransferase activity), and significant liver fibrosis (based on the FibroMeter [Echosens] nonalcoholic fatty liver disease score) in 1285 patients with suspected OSA in France. After adjusting for confounders including central obesity, the risk of liver steatosis increased with the severity of OSA (P for trend < ...
November 2016: Clinical Gastroenterology and Hepatology
Jérôme Boursier, Julien Vergniol, Anne Guillet, Jean-Baptiste Hiriart, Adrien Lannes, Brigitte Le Bail, Sophie Michalak, Faiza Chermak, Sandrine Bertrais, Juliette Foucher, Frédéric Oberti, Maude Charbonnier, Isabelle Fouchard-Hubert, Marie-Christine Rousselet, Paul Calès, Victor de Lédinghen
BACKGROUND & AIMS: NAFLD is highly prevalent but only a small subset of patients develop advanced liver fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis tests and liver stiffness measurement (LSM) by FibroScan for the diagnosis of liver fibrosis and the evaluation of prognosis in NAFLD. METHODS: Diagnostic accuracy was evaluated in a cross-sectional study including 452 NAFLD patients with liver biopsy (NASH-CRN fibrosis stage), LSM, and eight blood fibrosis tests (BARD, NAFLD fibrosis score, FibroMeter(NAFLD), aspartate aminotransferase to platelet ratio index (APRI), FIB4, FibroTest, Hepascore, FibroMeter(V2G))...
September 2016: Journal of Hepatology
Mohammad S Siddiqui, Kavish R Patidar, Sherry Boyett, Velimir A Luketic, Puneet Puri, Arun J Sanyal
BACKGROUND & AIMS: In non-alcoholic fatty liver disease, presence of fibrosis is predictive of long-term liver-related complications. Currently, there are no reliable and non-invasive means of quantifying fibrosis in those with non-alcoholic fatty liver disease. Therefore, we aimed to evaluate the performance of a panel of non-invasive models in predicting fibrosis in non-alcoholic fatty liver disease. METHODS: The accuracy of FibroMeter non-alcoholic fatty liver disease, fibrosis 4 and four other non-invasive models in predicting fibrosis in those with biopsy proven non-alcoholic fatty liver disease was compared...
April 2016: Liver International: Official Journal of the International Association for the Study of the Liver
Marta Kucharska, Marcin Inglot, Małgorzata Kuliszkiewicz-Janus, Monika Pazgan-Simon, Brygida Knysz
Haemophilia is an entity, wherein the HCV infection rate is greater than in the general population and ranges between 70-90%. The majority of HCV infections were acquired by hemophiliacs in the 1980s, by the use of infected cryoprecipitate or fresh frozen plasma preparations. It is therefore highly likely that many of them, more than twenty years after the infection, have developed advanced liver disease. Until recently, in order to assess its severity, it was necessary to perform a liver biopsy. Currently, we observe rapid developments of non-invasive methods that are particularly useful in patients with bleeding disorders...
July 2015: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
Sim Yee Ong, Lara Dolling, Jeannette L Dixon, Amanda J Nicoll, Lyle C Gurrin, Michelle Wolthuizen, Erica M Wood, Greg J Anderson, Grant A Ramm, Katrina J Allen, John K Olynyk, Darrell Crawford, Jennifer Kava, Louise E Ramm, Paul Gow, Simon Durrant, Lawrie W Powell, Martin B Delatycki
INTRODUCTION: HFE p.C282Y homozygosity is the most common cause of hereditary haemochromatosis. There is currently insufficient evidence to assess whether non-specific symptoms or hepatic injury in homozygotes with moderately elevated iron defined as a serum ferritin (SF) of 300-1000 µg/L are related to iron overload. As such the evidence for intervention in this group is lacking. We present here methods for a study that aims to evaluate whether non-specific symptoms and hepatic fibrosis markers improve with short-term normalisation of SF in p...
August 12, 2015: BMJ Open
Emmanuel A Tsochatzis, Laurent Castera
PURPOSE OF REVIEW: It is estimated that up to 10% of patients with HIV have chronic hepatitis C (HCV)-HIV coinfection in the Western world. Assessment of liver disease is essential in such patients in order to diagnose cirrhosis at an early stage, prioritize for anti-HCV treatment but also assess fibrosis regression after sustained viral response (SVR). In this review, we present a critical appraisal of liver disease assessment in patients with HIV-HCV co-infection. RECENT FINDINGS: Liver biopsy has largely been replaced by noninvasive fibrosis assessment in most coinfected patients, although it is still of value if there are concerns of additional diagnoses...
September 2015: Current Opinion in HIV and AIDS
Elif Dincses, Yusuf Yilmaz
BACKGROUND: Liver fibrosis is an important prognostic determinant in patients with nonalcoholic fatty liver disease (NAFLD). The FibroMeter VCTE is a diagnostic tool comprising both biochemical markers and transient elastography (TE) originally developed for the diagnosis of fibrosis in patients with chronic viral hepatitis. In this pilot study, we investigated the diagnostic performance of the FibroMeter VCTE tool for determining fibrosis in patients with biopsy-proven NAFLD. Its diagnostic accuracy was also compared with those of the NAFLD fibrosis score (NFSA) and TE alone...
October 2015: European Journal of Gastroenterology & Hepatology
Anil Arora, Praveen Sharma
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed as well as in developing countries. Its prevalence continues to rise currently affecting approximately 20-30% of adults and 10% of children in the United States. Non-alcoholic fatty liver disease represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign non-progressive clinical course, to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease...
June 2012: Journal of Clinical and Experimental Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"